ERIC 2018 | Integrating molecular and cellular therapies for CLL
Emili Montserrat
• 25 Oct 2018
Integrating molecular and cellular therapies for chronic lymphocytic leukemia (CLL) in this era of targeted therapy is an important task. Here, Emili Montserrat, MD, PhD, from the Hospital Clinic of Barcelona, Barcelona, Spain, discusses this issue, highlighting the use of biomarkers to guide therapy decision making, while pointing out the lag time between the discovery and incorporation of these markers into routine practice. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
